Modeling of presymptomatic and symptomatic stages of parkinsonism in mice

Neuroscience

Volumn 181, Issue , 2011, Pages 67-78

  Ugrumov, M V ^a,b   Khaindrava, V G ^a,b   Kozina, E A ^a,b   Kucheryanu, V G ^c   Bocharov, E V ^c   Kryzhanovsky, G N ^c   Kudrin, V S ^b,d   Narkevich, V B ^d   Klodt, P M ^d   Rayevsky, K S ^b   Pronina, T S ^a,b  

^a KOL TSOV INSTITUTE OF DEVELOPMENTAL BIOLOGY   (Russian Federation)

^b P K ANOKHIN INSTITUTE OF NORMAL PHYSIOLOGY   (Russian Federation)

^c INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^d INSTITUTE OF PHARMACOLOGY   (Russian Federation)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Brain; Dopamine; Mice; Nigrostriatal system; Parkinsonism

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN NERVE CELL; BRAIN REGION; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE MODEL; DOPAMINERGIC NERVE CELL; MALE; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NERVE FIBER; NIGRAL CELL BODY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL;

EID: 79953711110     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.03.006     Document Type: Article

References (76)

1. Abercrombie M. Estimation of nuclear population from microtome sections. Anat Res 1946, 94:239-247.
2. Agid Y. Parkinson's disease: pathophysiology. Lancet 1991, 337:1321-1324.
3. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989, 12:366-375.
4. Arluison M., Dietl M., Thibault J. Ultrastructural morphology of dopaminergic nerve terminals and synapses in the striatum of the rat using tyrosine hydroxylase immunocytochemistry: a topographical study. Brain Res Bull 1984, 13:269-285.
5. Berendse H.W., Booij J., Francot C.M., Bergmans P.L., Hijman R., Stoof J.C., Wolters E.C. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 2001, 50:34-41.
6. Bergstrom B.P., Garris P.A. "Passive stabilization" of striatal extracellular dopamine across the lesion spectrum encompassing the presymptomatic phase of Parkinson's disease: a voltammetric study in the 6-OHDA-lesioned rat. J Neurochem 2003, 87:1224-1236.
7. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973, 20:415-455.
8. Bezard E. Neuroprotection for Parkinson's disease: clinically driven experimental design in non-human primates. Parkinson's disease: molecular and therapeutic insights from model systems 2008, 65-76. Elsevier, Amsterdam. R. Nass, S. Przedborski (Eds.).
9. Bezard E., Dovero S., Bioulac B., Gross C.E. Kinetics of nigral degeneration in a chronic model of MPTP-treated mice. Neurosci Lett 1997, 234:47-50.
10. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A.R., Bioulac B., Brotchie J.M., Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001, 21:6853-6861.
11. Bezard E., Gross C.E. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog Neurobiol 1998, 55:93-116.
12. Bezard E., Gross C.E., Brotchie J.M. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 2003, 26:215-221.
13. Bezard E., Jaber M., Gonon F., Boireau A., Bloch B., Gross C.E. Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. Eur J Neurosci 2000, 12:2892-2900.
14. Boulet S., Mounayar S., Poupard A., Bertrand A., Jan C., Pessiglione M., Hirsch E.C., Feuerstein C., Francois C., Feger J., Savasta M., Tremblay L. Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis. J Neurosci 2008, 28:9575-9584.
15. Braak H., Ghebremedhin E., Rub U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004, 318:121-134.
16. Buhmann C., Arlt S., Kontush A., Moller-Bertram T., Sperber S., Oechsner M., Stuerenburg H.J., Beisiegel U. Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication. Neurobiol Dis 2004, 15:160-170.
17. Buttarelli F.R., Capriotti G., Pellicano C., Prosperi D., Circella A., Festa A., Giovannelli M., Tofani A., Pontieri F.E., Scopinaro F. Central and peripheral dopamine transporter reduction in Parkinson's disease. Neurol Res 2009, 31:687-691.
18. DeKosky S.T., Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science 2003, 302:830-834.
19. Ehringer H., Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 1960, 38:1236-1239.
20. Eller M., Williams D.R. Biological fluid biomarkers in neurodegenerative parkinsonism. Nat Rev Neurol 2009, 5:561-570.
21. Fahn S. How do you treat motor complications in Parkinson's disease: medicine, surgery, or both?. Ann Neurol 2008, 64(Suppl 2):S56-S64.
22. Gerfen M., Herkenham M., Thibault J. The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J Neurosci 1987, 7:3915-3934.
23. Gerlach M., Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 1996, 103:987-1041.
24. Gibrat C., Saint-Pierre M., Bousquet M., Levesque D., Rouillard C., Cicchetti F. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions. J Neurochem 2009, 109:1469-1482.
25. Gobert A., Billiras R., Cistarelli L., Millan M.J. Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by alpha2-autoreceptors. J Neurosci Methods 2004, 140:141-152.
26. Goldstein D.S., Holmes C., Bentho O., Sato T., Moak J., Sharabi Y., Imrich R., Conant S., Eldadah B.A. Biomarkers to detect central dopamine deficiency and distinguish Parkinson's disease from multiple system atrophy. Parkinsonism Relat Disord 2008, 14:600-607.
27. Goldstein D.S., Holmes C., Li S.T., Bruce S., Metman L.V., Cannon R.O. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med 2000, 133:338-347.
28. Greenwood C.E., Tatton W.G., Seniuk N.A., Biddle F.G. Increased dopamine synthesis in aging substantia nigra neurons. Neurobiol Aging 1991, 12:557-565.
29. Halliday G.M., Blumbergs P.C., Cotton R.G., Blessing W.W., Geffen L.B. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res 1990, 510:104-107.
30. Herkenham M., Little M.D., Bankiewicz K., Yang S.C., Markey S.P., Johannessen J.N. Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 1991, 40:133-158.
31. Ho A., Blum M. Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease. J Neurosci 1998, 18:5614-5629.
32. Izvolskaia M., Duittoz A.H., Tillet Y., Ugrumov M.V. The influence of catecholamine on the migration of gonadotropin-releasing hormone-producing neurons in the rat foetuses. Brain Struct Funct 2009, 213:289-300.
33. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995, 4:257-269.
34. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2007, 2:141-151.
35. Jackson-Lewis V., Przedborski S. The MPTP mouse model of Parkinson's disease: the true, the false and the unknown. Parkinson's disease: molecular and therapeutic insights from model systems 2008, 147-158. Elsevier, Amsterdam. R. Nass, S. Przedborski (Eds.).
36. Kryzhanovsky G.N., Kucheryanu V.G., Krupina N.A., Pozdnyakov O.M., Kladkevich E.B., Nikushkin E.V., Oomura Y. Effects of fibroblast growth factors on MPTP-induced parkinsonian syndrome in mice. Pathophysiology 1997, 4:59-67.
37. Kurosaki R., Muramatsu Y., Watanabe H., Michimata M., Matsubara M., Imai Y., Araki T. Role of dopamine transporter against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice. Metab Brain Dis 2003, 18:139-146.
38. Langston J.W., Forno L.S., Rebert C.S., Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 1984, 292:390-394.
39. Le W.D., Rowe D.B., Jankovic J., Xie W., Appel S.H. Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch Neurol 1999, 56:194-200.
40. Linder J.C., Klemfuss H., Groves P.M. Acute ultrastructural and behavioral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice. Neurosci Lett 1987, 82:221-226.
41. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S., Herkenham M.A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984, 311:464-467.
42. Maruyama W., Abe T., Tohgi H., Naoi M. An endogenous MPTP-like dopaminergic neurotoxin, N-methyl(R)salsolinol, in the cerebrospinal fluid decreases with progression of Parkinson's disease. Neurosci Lett 1999, 262:13-16.
43. Maruyama W., Nakahara D., Ota M., Takahashi T., Takahashi A., Nagatsu T., Naoi M. N-methylation of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, (R)-salsolinol, in rat brains: in vivo microdialysis study. J Neurochem 1992, 59:395-400.
44. McCallum S.E., Parameswaran N., Perez X.A., Bao S., McIntosh J.M., Grady S.R., Quik M. Compensation in pre-synaptic dopaminergic function following nigrostriatal damage in primates. J Neurochem 2006, 96:960-972.
45. Meissner W., Hill M.P., Tison F., Gross C.E., Bezard E. Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trends Pharmacol Sci 2004, 25:249-253.
46. Nagatsu T. Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci Res 1997, 29:99-111.
47. Nakazato T., Akiyama A. Differential time courses of exogenous 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine and its metabolite MPP+ in the rat striatum and nucleus accumbens measured using in vivo voltammetry. Brain Res 1998, 812:150-156.
48. Naoi M., Maruyama W., Akao Y., Zhang J., Parvez H. Apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopamine neurons. Toxicology 2000, 153:123-141.
49. Naoi M., Maruyama W., Dostert P., Hashizume Y. N-methyl-(R)salsolinol as a dopaminergic neurotoxin: from an animal model to an early marker of Parkinson's disease. J Neural Transm Suppl 1997, 50:89-105.
50. Nelson E., Liang C., Sinton C., German D. Midbrain dopaminergic neurons in the mouse: computer-assisted mapping. J Comp Neurol 1996, 369:361-371.
51. Nirenberg M.J., Vaughan R.A., Uhl G.R., Kuhar M.J., Pickel V.M. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 1996, 16:436-447.
52. Niwa T., Maruyama W., Nakahara D., Takeda N., Yoshizumi H., Tatematsu A., Takahashi A., Dostert P., Naoi M., Nagatsu T. Endogenous synthesis of N-methylsalsolinol, an analogue of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, in rat brain during in vivo microdialysis with salsolinol, as demonstrated by gas chromatography-mass spectrometry. J Chromatogr 1992, 578:109-115.
53. Obeso J.A., Rodriguez-Oroz M.C., Javier Blesa F., Guridi J. The globus pallidus pars externa and Parkinson's disease. Ready for prime time?. Exp Neurol 2006, 202:1-7.
54. Paxinos G., Franklin K. The mouse brain in stereotaxic coordinates 2001, Academic Press, London. 2nd edition.
55. Petroske E., Meredith G.E., Callen S., Totterdell S., Lau Y.S. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 2001, 106:589-601.
56. Petrucelli L., Dickson D. Neuropathology of Parkinson's disease. Parkinson's disease: molecular and therapeutic insights from model systems 2008, 35-48. Elsevier, Amsterdam. R. Nass, S. Przedborski (Eds.).
57. Porras G., Bezard E. Preclinical development of gene therapy for Parkinson's disease. Exp Neurol 2008, 209:72-81.
58. Prunier C., Bezard E., Montharu J., Mantzarides M., Besnard J.C., Baulieu J.L., Gross C., Guilloteau D., Chalon S. Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT. Neuroimage 2003, 19:810-816.
59. Raff M.C., Whitmore A.V., Finn J.T. Axonal self-destruction and neurodegeneration. Science 2002, 296:868-871.
60. Riederer P., Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 1976, 38:277-301.
61. Ries V., Silva R.M., Oo T.F., Cheng H.C., Rzhetskaya M., Kholodilov N., Flavell R.A., Kuan C.Y., Rakic P., Burke R.E. JNK2 and JNK3 combined are essential for apoptosis in dopamine neurons of the substantia nigra, but are not required for axon degeneration. J Neurochem 2008, 107:1578-1588.
62. Rousselet E., Joubert C., Callebert J., Parain K., Tremblay L., Orieux G., Launay J.M., Cohen-Salmon C., Hirsch E.C. Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice. Neurobiol Dis 2003, 14:218-228.
63. Sandyk R., Iacono R.P., Bamford C.R. The hypothalamus in Parkinson disease. Ital J Neurol Sci 1987, 8:227-234.
64. Schenck C.H., Bundlie S.R., Mahowald M.W. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996, 46:388-393.
65. Schmidt N., Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm 2001, 108:1263-1282.
66. Schneider J., Anderson D., Decamp E. Neuropathology of Parkinson's disease. Parkinson's disease: molecular and therapeutic insights from model systems 2008, 87-104. Elsevier, Amsterdam. R. Nass, S. Przedborski (Eds.).
67. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 2001, 125:109-125.
68. Sonsalla P.K., Zeevalk G.D., German D.C. Chronic intraventricular administration of 1-methyl-4-phenylpyridinium as a progressive model of Parkinson's disease. Parkinsonism Relat Disord 2008, 14(Suppl 2):S116-S118.
69. Sossi V., de La Fuente-Fernandez R., Holden J.E., Doudet D.J., McKenzie J., Stoessl A.J., Ruth T.J. Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. J Cereb Blood Flow Metab 2002, 22:232-239.
70. Tillerson J.L., Caudle W.M., Reveron M.E., Miller G.W. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp Neurol 2002, 178:80-90.
71. Tolosa E., Compta Y., Gaig C. The premotor phase of Parkinson's disease. Parkinsonism Relat Disord 2007, 13(Suppl):S2-S7.
72. Tuszynski M.H. Growth-factor gene therapy for neurodegenerative disorders. Lancet Neurol 2002, 1:51-57.
73. Ugrumov M.V. Brain neurons partly expressing monoaminergic phenotype: distribution, development, and functional significance in norm and pathology. Handbook of neurochemistry and molecular neurobiology (Lajtha A, ed), Neurotransmitter systems 2008, 21-73. Springer, New York. S. Vizi (Ed.).
74. Ugrumov M.V. Non-dopaminergic neurons partly expressing dopaminergic phenotype: distribution in the brain, development and functional significance. J Chem Neuroanat 2009, 38:241-256.
75. Zigmond M.J. Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of Parkinsonism. Neurobiol Dis 1997, 4:247-253.
76. Zigmond M.J., Abercrombie E.D., Berger T.W., Grace A.A., Stricker E.M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 1990, 13:290-296.